Treatment of Type-1 Hepatorenal Syndrome Associated With Sepsis

NACompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

July 31, 2013

Study Completion Date

August 31, 2013

Conditions
Hepatorenal Syndrome
Interventions
DRUG

Terlipressin and albumin

"Single-group study (Type-1 Hepatorenal Syndrome Associated With Active Infections) Terlipressin was initially given at a dose of 1 mg/4h as an intravenous bolus for 2 days. If at day 3 serum creatinine had decreased at least 25% of the pretreatment values, the dose of terlipressin was not modified. In the remaining patients, the dose was increased up to a maximum of 2 mg/4h. Terlipressin was given until serum creatinine had decreased below 1.5 mg/dL (133 µmol/L) or for a maximum of 14 days.~In addition to terlipressin, all patients received albumin at a dose of 1g per kg body weight during the first 24 hours, followed by 40g daily,targeted to obtain a central venous pressure (CVP) between 10 and 15 cm of water."

Trial Locations (1)

08036

Hospital Clinic de Barcelona, Barcelona

All Listed Sponsors
lead

Hospital Clinic of Barcelona

OTHER

NCT01932151 - Treatment of Type-1 Hepatorenal Syndrome Associated With Sepsis | Biotech Hunter | Biotech Hunter